Drug intelligence / Profile preview

BetaGraft

Development stage: Preclinical
Lead developer: Beta-cell
Modality: Cell Therapies
Administration: Subcutaneous

Overview

BetaGraft is a xenogeneic cell therapy candidate being developed by Beta-Cell NV for the treatment of Type 1 diabetes. The product consists of porcine-derived endocrine cells, specifically insulin-producing beta cells and glucagon-producing alpha cells, which are isolated and prepared using the proprietary BetaPrep process. These cells are formulated within a biocompatible gel matrix and implanted subcutaneously. The mechanism of action involves the physiological secretion of insulin and glucagon in response to blood glucose levels, thereby replacing the lost endocrine function of the pancreas and restoring glycemic control. BetaGraft is currently in the preclinical stage of development and aims to provide a functional cure by mimicking the natural endocrine regulation of the pancreas.

Brand names: BetaGraft

Beyond the preview

Go deeper on BetaGraft.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BetaGraft.

Explore the full profile